CYP19A1 and invasive breast carcinoma: Using the chi‐square test, the prevalence of malignant BrCa was significantly lower (p < 0.001) and the prevalence of aromatase inhibitors was significantly higher (p = 0.033) for BrCa+/CIPN+ as compared to BrCa+/CIPN−; no other group differences were observed.